CPC C07K 16/2893 (2013.01) [A61K 47/549 (2017.08); A61K 47/6803 (2017.08); A61K 47/6869 (2017.08); A61K 47/6889 (2017.08); C07K 16/28 (2013.01); C07K 16/2809 (2013.01); C07K 16/2851 (2013.01); C07K 16/32 (2013.01); C07K 16/40 (2013.01); C07K 2317/40 (2013.01); C07K 2317/41 (2013.01); C07K 2317/522 (2013.01); C07K 2317/56 (2013.01); C07K 2317/71 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01)] | 17 Claims |
1. A method of treating HER2 positive cancer in a patient in need thereof comprising administering an effective amount of a composition comprising: an antibody, or antigen binding fragment thereof, that binds to human HER2 and comprises a CH1 domain,
wherein the CH1 domain comprises an asparagine residue at amino acid position 114, according to Kabat numbering.
|